Danaher Corporation arrives at its July 21 Q2 print with bears in full retreat and the options market tilting modestly more cautious — a shift from the relaxed tone noted just ten days ago.
The short retreat has accelerated since the July 8 note. SI as a percentage of the free float has now fallen to 1.4%, down 15% over the past week alone — extending the unwind from the late-June peak near 2% that earlier coverage flagged. The June rebuild and subsequent collapse is visible in the history data: from around 13 million shares short at the end of June, positions have dropped to under 9.7 million. Borrow conditions remain completely frictionless, with over 700 million shares available in the lending pool and cost to borrow at 0.45% — up 39% on the week in percentage terms but still trivially low in absolute terms. There is no squeeze pressure here. What has changed is the options tone: the put/call ratio has nudged up to 0.60, just over one standard deviation above its 20-day average of 0.54. That's a modest shift toward hedging, not a defensive alarm, but it marks a direction change from the sub-average PCR reported a week ago.
The analyst community is broadly constructive but selectively trimming. The consensus mean target of $242 implies about 19% upside from the current $203.83, and positive ratings dominate — Evercore ISI, HSBC, Citigroup, RBC Capital and Morgan Stanley all hold bullish or equivalent ratings. The direction of travel is lower, however: most recent target adjustments have been cuts, with Morgan Stanley reducing to $255 from $270 and HSBC moving to $230 from $270 earlier in the summer. Piper Sandler's June initiation at a $200 neutral target — essentially flat to the current price — frames the bear case most starkly. Bulls point to the $4.9 billion performance obligation backlog and an expected life sciences growth ramp, with the EPS 12-month forward year-on-year increase factor scoring in the 100th percentile. Bears counter that only 46% of those obligations are expected to convert to revenue within 12 months, down from 48% the prior quarter, and that China headwinds and foreign exchange pressure continue to cloud the near-term outlook. The PE multiple has expanded by roughly 3 turns over the past month to 23x, compressing the margin of safety for a stock that has underperformed peers year-to-date. Thermo Fisher and Mettler-Toledo both gained over 3.5% on the week; managed 2.4%.
Insider activity adds a small cautionary note. Three insiders sold shares on July 15 — two independent directors and the Chief Accounting Officer — at prices just under $201. The trades were small, all carrying significance scores of 1, and likely reflect routine plan-based selling. Net insider activity over 90 days is marginally positive at roughly $769,000, so this is not a directional signal. The Rales brothers, co-founders who together hold over 10% of shares, have shown no meaningful movement in recently reported positions, leaving the ownership picture stable.
The Q2 print will test whether the bioprocessing recovery is tracking the timeline management outlined in April — a question the Street has been discounting unevenly, as the gap between the $242 consensus target and the $200 neutral initiations illustrates.
See the live data behind this article on ORTEX.
Open DHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
